1. Home
  2. TRNR vs JAGX Comparison

TRNR vs JAGX Comparison

Compare TRNR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Interactive Strength Inc.

TRNR

Interactive Strength Inc.

HOLD

Current Price

$1.78

Market Cap

5.9M

Sector

Technology

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$1.34

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNR
JAGX
Founded
2017
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
3.9M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
TRNR
JAGX
Price
$1.78
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
236.4K
378.5K
Earning Date
11-14-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,774,000.00
$11,785,000.00
Revenue This Year
$578.14
$22.41
Revenue Next Year
$130.65
$30.00
P/E Ratio
N/A
N/A
Revenue Growth
207.36
12.45
52 Week Low
$1.60
$1.00
52 Week High
$39.60
$33.25

Technical Indicators

Market Signals
Indicator
TRNR
JAGX
Relative Strength Index (RSI) 35.44 47.04
Support Level $1.81 $1.05
Resistance Level $2.42 $1.36
Average True Range (ATR) 0.22 0.14
MACD 0.00 0.04
Stochastic Oscillator 18.92 70.00

Price Performance

Historical Comparison
TRNR
JAGX

About TRNR Interactive Strength Inc.

Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: